Methyl (2Z)-3-iodoprop-2-enoate, C₄H₅IO₂, molecular mass 211.99 g mol⁻¹, is supplied as a Pharma Grade API for tablet, capsule, granule, injection, oral, and injectable applications. The (Z)-designation defines the cis relationship between the C-3 iodine and the methyl carboxylate across the α,β-unsaturated system. This geometric identity is analytically controlled because the E-isomer differs in dipolar character, chromatographic retention, thermal stability, and downstream reactivity. The product is not assigned a harmonized monograph in USP or Ph. Eur.; therefore release specifications are established under an ICH Q6A-compliant in-house specification and supported by certificates of analysis with traceability to qualified secondary standards. Where a supplier model designation is used, it generally encodes the Z-configuration and the intended dosage-route grade; the base molecular entity is identical across tablet, capsule, granule, and injectable presentations, with differentiation residing in residual solvent profile, particle-size distribution, bioburden, endotoxin load, and packaging. The material is provided in amber glass or fluoropolymer-lined containers under inert headspace, with packaging selected to limit photolytic and hydrolytic degradation.

The structural formula contains a vinyl iodide at the β-carbon and a methyl ester at the α-carbon in a cis arrangement. This topology increases molecular polarizability and polar surface-area character relative to the corresponding bromo or chloro esters, while lowering the carbon–halogen bond dissociation energy. The same reactivity that makes the compound a versatile intermediate in palladium-catalyzed coupling also imposes storage and processing boundaries: the ester is susceptible to hydrolysis under aqueous alkaline conditions, and the vinyl iodide may undergo deiodination, nucleophilic vinylic substitution, or geometric isomerization under radical, photolytic, or strongly basic stress. For this reason, release methods specifically quantify the E-isomer, free iodide, and deiodinated or hydrolyzed by-products rather than relying on total purity alone.

What release limits and ICH-aligned control elements apply to the (Z)-isomer?

Because a pharmacopoeial monograph is not harmonized for this specific (Z)-configured ester, the release framework in Table 1 is derived from ICH Q6A, ICH Q3A(R2), ICH Q3C(R8), ICH Q3D, and relevant USP general chapters. The limits are representative; route-specific acceptance criteria must be justified by the maximum daily dose, finished-product formulation, and intended patient population. For oral solid and parenteral grades, the same stereochemical purity requirement is applied, but endotoxin, particulate matter, and residual solvent expectations differ according to route.

The specification above is a vendor release framework, not a regulatory upper bound for all dosage forms. Finished-product manufacturers are expected to evaluate dose-dependent limits for elemental impurities, residual solvents, and any potential degradation products according to the intended maximum daily dose and route of administration. Published compendial data for this specific (Z)-configured molecule are limited; therefore forced-degradation studies and multivariate release data from the actual manufacturing stream are required to confirm the suitability of the proposed limits.

For tablet, capsule, and granule manufacture, the neat substance may be a low-melting solid or oil at ambient temperature. Direct compression of the unmilled material is not generally practiced because of poor flow and potential segregation. Instead, the API is first adsorbed onto microcrystalline cellulose, pregelatinized starch, or colloidal silicon dioxide in a low-shear or high-shear mixer with the jacket held at 15–25 °C. High-shear chopper operation is limited to intervals below 60 s to prevent localized heating that can promote E-isomer formation or ester degradation. When a granulation process is required, ethanolic or isopropanolic binder solutions are preferred over aqueous solutions to limit hydrolysis. Drying in a fluid-bed dryer at inlet air 40–55 °C is adjusted to maintain loss-on-drying below 0.5%. Lubrication with magnesium stearate at 0.5–1.0% (w/w) and colloidal silicon dioxide at 0.5% (w/w) is typical; excessive hydrophobic lubricant may extend disintegration beyond 15 min and should be qualified during formulation development. Tablet compression on a rotary press is generally targeted at 5–8 kp hardness, with friability not exceeding 1.0% after 100 revolutions according to USP <1216>. Capsule filling on dosator or tamping-pin equipment is conducted at relative humidity ≤ 40% RH, with granule D90 ≤ 200 µm to reduce sticking and ensure weight uniformity. Content uniformity testing follows USP <905>; for dose strengths below 10 mg, a finer particle-size fraction with D90 ≤ 150 µm may be necessary. These processing ranges are conservative starting points derived from behavior of analogous α,β-unsaturated esters; published data for this specific configuration are limited and should be supplemented with trial-batch data.

The primary lot-to-lot variability observed in production-scale handling is residual solvent content rather than stereochemical purity. Headspace gas chromatography according to USP <467> is therefore performed on each batch. Residual methyl tert-butyl ether, ethyl acetate, or isopropanol may be present depending on the supplier’s crystallization and drying route; each must be controlled below its permitted daily exposure before the batch is released for oral or injectable use. Low-shear tumble blending with an intensifier bar not exceeding 15 Hz is preferred because the API can degrade at high local shear when dry or when friction against stainless-steel surfaces generates heat.

Injectable-grade processing boundaries and terminal-sterilization incompatibilities

Injectable dosage forms containing the (Z)-ester are usually prepared with non-aqueous, non-nucleophilic co-solvents because the methyl ester is hydrolytically labile. When an aqueous formulation is unavoidable, the pH should be maintained between 4.0 and 6.5 unless forced-degradation data support a wider range. The formulation is monitored for free iodide and acrylic acid derivatives, both of which indicate degradation. Terminal steam sterilization at 121 °C for 15 min is not recommended without thermal cycling studies; if terminal sterilization is mandatory, a lower-temperature cycle at 115 °C for 30 min bracketed across the intended fill volume should be evaluated because the vinyl iodide and methyl ester groups may undergo hydrolysis, deiodination, or geometric isomerization. Aseptic filtration through a 0.22 µm polyethersulfone, PVDF, or PTFE membrane is preferred. Nylon membranes containing amine-like groups are considered incompatible because of potential nucleophilic interaction with the α,β-unsaturated ester. The API as supplied is not represented as sterile; downstream aseptic processing under EU GMP Annex 1 and ISO 14644-1 class 5 conditions is required for injectable manufacture.

For lyophilized parenterals, the bulk solution is filtered below room temperature and filled into depyrogenated vials. Primary drying is typically performed at shelf temperature −20 °C to −10 °C with chamber pressure 0.1–0.3 mbar. Collapse of the lyophilized cake may occur if the product temperature exceeds the glass transition or eutectic boundary of the formulation; this boundary must be measured for each combination of co-solvent, buffer, and bulking agent. Dry-heat depyrogenation of vials at 250 °C is compatible with parenteral packaging but does not compensate for an endotoxin-above-limit API. Injectable-grade material should be assessed against USP <788> particulate matter limits after reconstitution or dilution. Non-aqueous vehicles may require pre-filtration through a 0.45 µm membrane before the final 0.22 µm sterile filtration to protect membrane loading and maintain flux. Published data for this specific configuration in terminal sterilization cycles are limited; therefore terminal sterilization should not be substituted for aseptic processing without product-specific thermal stability data.

When the E-isomer or lighter halide esters are substituted, the processing envelope changes

Differentiation between the (Z)-configured ester and its E-isomer is performed by reversed-phase HPLC under conditions yielding baseline resolution of at least 2.0. As a confirmatory method, ¹H NMR of the (Z)-isomer shows the olefinic vicinal coupling constant generally between 8 Hz and 12 Hz, whereas the E-isomer generally exhibits a trans coupling of 14–17 Hz. The E-isomer may elute as a discrete peak, but relative retention is column-specific and cannot be assumed without development on the actual analytical column batch. A chromatographic method with area normalization alone may be insufficient if the E-isomer and the parent have significantly different response factors; linearity and relative-response-factor determination are therefore included in method validation.

Compared with the E-isomer, the (Z)-configured iodide places the C–I and carbonyl groups on the same face of the double bond. This spatial arrangement can influence metal-catalyzed oxidative addition, migratory insertion, and subsequent coupling selectivity in Sonogashira, Heck, or Stille-type sequences. The E-isomer may exhibit different reactivity in hydrophobic binding environments or different crystallization behavior; it is not interchangeable with the (Z)-compound in a validated API process unless the supplier demonstrates equivalent control and impurity fate. Compared with methyl 3-bromopropenoate, the iodinated analogue contains a lower carbon–halogen bond dissociation energy and a more polarizable leaving group, which can increase coupling rate but reduce photostability and thermal robustness. Compared with the corresponding chloro or unhalogenated methyl acrylate, the iodinated material has higher molecular mass and a greater potential for free-iodide release under stress. Confusion with methyl 3-iodopropanoate, the saturated analogue, should be avoided: the saturated compound lacks the α,β-unsaturated system and therefore has different chemical, toxicological, and processing properties. The 2-iodo positional isomer, in which iodine is attached at the α-carbon, also differs in electron-withdrawing environment, hydrolysis product profile, and coupling behavior.

For use as an active pharmaceutical ingredient rather than as a cGMP intermediate, published nonclinical and clinical data for this specific molecule are limited. The designation of a material as pharma-grade does not by itself establish safety, efficacy, or a permitted daily intake. If the substance is used as an isolated active in tablet, capsule, granule, or injectable dosage forms, the applicant must establish its own quality, stability, and nonclinical packages under ICH Q1A(R2), ICH Q3B(R2), and ICH M3(R2). A vendor certificate of analysis and a route-specific specification are necessary but not sufficient for marketing authorization or for manufacture of a finished pharmaceutical product.

Storage conditions for the unopened container are maintained at +2 °C to +8 °C, protected from light, under argon or nitrogen. Once opened, the material should be used within 24 h under controlled relative humidity; if transfer is required, containers of borosilicate glass or fluoropolymer-lined aluminum are preferred over low-density polyethylene, which permits oxygen and moisture ingress. The compound is segregated from bases, primary and secondary amines, thiols, strong nucleophiles, and oxidizing agents. Aqueous solutions should be prepared fresh and, if held at room temperature for more than 4 h, require pH control and purity monitoring. Disposal and handling should follow local halogenated waste requirements and the safety data sheet; no conclusion regarding long-term stability beyond the vendor’s assigned retest date is drawn from the release specification alone.